GlassScriptPhysician profile
Lois B Moss
NPI 1598047706
$3,626.17
in general payments reported to CMS, 2019-2025
33 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,429 · 2023: $296 · 2024: $197 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $478.21 | 2021-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $411.05 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.35 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $254.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $231.28 | 2021-2023 | |
| Abbvie INC. | $216.47 | 2021-2022 | |
| Pfizer INC. | $171.39 | 2021-2025 | |
| Novo Nordisk INC | $137.69 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $135.06 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.49 | 2022-2023 | Xifaxan, Trulance |
| Amgen INC. | $123.28 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $96.96 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $93.94 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $93.52 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $85.98 | 2023-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $73.64 | 2021-2022 | |
| Dexcom, INC. | $66.14 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.49 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $49.26 | 2021 | |
| Aimmune Therapeutics, INC. | $42.42 | 2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.87 | 2022 | |
| Upsher-Smith Laboratories LLC | $36.60 | 2021 | |
| Organon LLC | $35.31 | 2021-2022 | |
| Eisai INC. | $32.93 | 2021 | |
| Abbott Laboratories | $32.03 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $30.24 | 2021 | |
| Nevro Corp. | $22.12 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.30 | 2022 | |
| Lundbeck LLC | $17.49 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $15.26 | 2021 | |
| Boston Scientific Corporation | $13.67 | 2025 | Intracept |
| Grt US Holding, INC. | $13.37 | 2022 | |
| Metacel Pharmaceuticals LLC | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lois Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.